ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

4:15PM-4:30PM: Abstract Number: 2638

ASembleNet: A Hybrid AI Model for MRI-Based Classification of Ankylosing Spondylitis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Advances in Axial Spondyloarthritis (2633–2638)

4:15PM-4:30PM: Abstract Number: 2614

Impact of Vagus Nerve-Mediated Neuroimmune Modulation on structural joint damage using Gd-MRI RAMRIS imaging in Biologic-Experienced Patients with Rheumatoid Arthritis

Abstracts: Imaging of Rheumatic Diseases (2609–2614)

4:15PM-4:30PM: Abstract Number: 2626

Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo: Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07)

Abstracts: Osteoarthritis – Clinical (2621–2626)

4:15PM-4:30PM: Abstract Number: 2632

Maternal vascular malperfusion: association with adverse perinatal outcomes in lupus pregnancies

Abstracts: Reproductive Issues in Rheumatic Disorders (2627–2632)

4:15PM-4:30PM: Abstract Number: 2608

Metabolic dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiac Manifestations in Psoriasis

Abstracts: ARP II: Perception, Prediction, and Prevention (2603–2608)

4:15PM-4:30PM: Abstract Number: 2620

Transition Success of Pediatric Rheumatology Patients: A Novel Scoring System

Abstracts: Measures & Measurement of Healthcare Quality (2615–2620)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].